Asymptomatic lung disease caused by Mycobacterium kansasii as an opportunistic infection in a patient treated with natalizumab for relapsing–remitting multiple sclerosis
Restricted accessLetterFirst published online April, 2014
Asymptomatic lung disease caused by Mycobacterium kansasii as an opportunistic infection in a patient treated with natalizumab for relapsing–remitting multiple sclerosis
MercurioARuggeriSAltieriM. 2011. Rickettsial infection in a multiple sclerosis patient treated with TysabriÆ: a case report. Mult Scler J17(10 suppl), S356-S357.
2.
RimintonDSHartungHPReddelSW2011. Managing the risks of immunosuppression. Curr Opin Neurol24, 217–223.
3.
SiddiqiSHRüsch-GerdesS.2006. Procedure Manual for BACTEC MGIT 960 TB System, July2006.
4.
PavlikIFalkinhamJOIIIKazdaJ2009. Environments providing favourable conditions for the multiplication and transmission of mycobacteria. In: KazdaJPavlikIFalkinhamJOIIIHruskaK (Ed.). The Ecology of Mycobacteria: Impact on Animal’s and Human’s health. Springer Science+Business Media B.V., pp.89–198.
5.
KubinM.SvandovaE.MedekB.ChobotS.OlsovskyZ.1980. Mycobacterium kansasii infection in an endemic area of Czechoslovakia. Tubercle61(4), 207–212.
